ADC Therapeutics (ADCT) said Wednesday that updated data from its phase 1b clinical trial evaluating the safety and efficacy of Zynlonta in combination with glofitamab supported a potential best-in-class regimen in patients with relapsed or refractory diffuse large B-cell lymphoma.

Results demonstrated an overall response rate of 89.8% and complete response rate of 77.6%, with the combination being well-tolerated in general and having a manageable safety profile, the company said.

The updated data is based on investigator assessment across 49 efficacy-evaluable patients with a minimum of six months of follow-up, ADC said.

Enrollment in the clinical trial is ongoing, with complete enrollment of approximately 100 patients in H1 of 2026, the company said.

ADC said it plans to share full data at a medical meeting and submit for publication by the end of 2026.